Sarepta Seeks to Strengthen Elevidys’ Case With Data in Older Kids
Since Elevidys’ first approval in 2023, experts have been clamoring for more data, particularly in older and non-ambulatory children. New results, presented Friday, show mobility improvements in 8- to 9-year-old patients after one year of follow-up.
Sarepta Seeks to Strengthen Elevidys’ Case With Data in Older Kids Read More »
